Fostering Trust at FDA
This article was originally published in RPM Report
Executive Summary
Joshua Sharfstein left his post as principle deputy commissioner of the Food & Drug Administration in January, leaving behind a short but productive legacy of increasing the level of transparency at FDA. Just before he left to become Maryland’s Secretary of Health and Mental Hygiene, he discussed transparency at the FDA/CMS Summit for Biopharmaceutical Executives. Here are excerpts from Sharfstein’s speech.
You may also be interested in...
Lessons Learned: How Avandia is Changing the Way FDA Does Business
FDA learned two important lessons from the Avandia debacle. First, the agency needs to be a better communicator—which means telling the public more about what it knows (and doesn’t know) about the safety of marketed products. But Avandia is also leading the agency to rethink what should be required to demonstrate safety, especially for chronic care therapies. Both could mean big changes for industry.
Sending a Message: FDA Leadership Responds to McNeil Recall
Deputy Commissioner Josh Sharfstein told a House committee investigating J&J's consumer products recall that the agency is "sending a message to industry" that it is getting tougher on manufacturing compliance. Here is his prepared testimony.